159.4 billion eye market, the competition will be white hot in the future

[pharmaceutical network market analysis] recently, Japan's towering pharmaceutical company announced that it has selected industrial land in Suzhou Industrial Park for the construction of a new pharmaceutical factory of towering Pharmaceutical (China) Co., Ltd It is reported that tafluoroprost (eye drops, trade name "typros") is the main product for the treatment of glaucoma in the Department of medicine It was selected as the medical insurance payment product in the medical insurance negotiation in 2019, with a price reduction of 72.3% and medical insurance payment price of 74.8 yuan According to the person in charge, the new product supply factory of Shengtian pharmaceutical is mainly because the ophthalmology market in China is expanding with the increasing number of patients and the continuous improvement of the medical and health system In order to further support China's business development, it is necessary to build new factories to ensure adequate supply and good quality of products, and further enhance the competitiveness of enterprises In fact, eye diseases have always been the focus of attention in China Taking myopia as an example, it has been reported that by the end of 2018, 90% of 20-year-old young people in China had myopia At the same time, with the aggravation of population aging, the total number of presbyopia over 45 years old in China is 391 million, which is expected to reach 461 million in 2023 In addition, the number of ophthalmic outpatients in China has also increased from 87.4 million in 2012 to about 109 million in 2016, with a compound annual growth rate of 5.8% The scale is expected to reach 140 million people in 2021, or a compound growth rate of 5.1% in 2016-2021 Other data show that from 2013 to 2017, China's eye market grew from 46.7 billion yuan to 86.6 billion yuan, with an average compound growth rate of 16.7% With the increasing incidence rate of ophthalmic diseases, the upgrading of ophthalmic treatment technology and the improvement of patients' awareness of diagnosis and treatment, it is estimated that the domestic ophthalmic market will reach 159 billion 400 million yuan by 2021, and the compound annual growth rate is expected to remain at 13.9% Thanks to the continuous expansion of domestic ophthalmic market, ophthalmic enterprises are also starting to speed up market layout and compete for market share Especially in 2019, the merger and acquisition among pharmaceutical enterprises is speeding up, and the market competition is becoming increasingly fierce At present, it includes foreign pharmaceutical giants such as Japan skyrocketing, Novartis, Alcon, etc and domestic ophthalmic pharmaceutical enterprises that are rapidly rising Kanghong pharmaceutical, Zhongsheng pharmaceutical, Xingqi ophthalmic pharmaceutical, Zhuhai Yisheng, etc are also in the plus code position For example, in recent years, Hengrui pharmaceutical specially spent a lot of money to introduce two innovative ophthalmic drugs from Germany to enter the ophthalmic drug market It is reported that the two drugs are mainly used for dry eye After the agreement is reached, Hengrui will obtain the rights of clinical development, production and marketing of the two products in China
In the future, with the continuous development of medical basic research, clinical research and medical engineering technology, ophthalmic drugs and surgery technology may be more significantly developed, including the clinical application of OCT angiography Technology (octa), all femtosecond laser surgery for myopia, glaucoma surgery, advancement of intraocular lens surgery technology and robot minimally invasive ophthalmic surgery, and these new drugs and technologies also It will provide a more solid technical guarantee for the continuous expansion of ophthalmic diagnosis and treatment market, and the outbreak of ophthalmic market is just around the corner.